Cargando…
Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia
BACKGROUND: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) and adult onset Still’s disease (AOSD). OBJECTIVE: Aim of this study was to estimate the budget impact of the...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AboutScience
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677608/ https://www.ncbi.nlm.nih.gov/pubmed/36627970 http://dx.doi.org/10.33393/grhta.2020.2140 |